Out of more than 200 cannabis stocks, there’s four that we’re going to be watching as the markets open due to breaking news out this morning.
Here’s four cannabis companies to watch today including Aphria Inc. (TSX:APH) (OTC:APHQF) and more.
Aphria Inc. (TSX:APH) (OTC:APHQF)
This morning, in conjunction with Tetra Bio-Pharma Inc., Aphria Inc. announced that it will start promoting a co-developed medical cannabis blend product under Health Canada’s Access to Cannabis for Medical Purposes Regulations, a.k.a. ACMPR. Tetra has signed a distribution agreement with Aphria to sell “Rx Princeps”, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.
Emerald Health Therapeutics Inc. (TSXV:EMH) (OTC:EMHTF)
This morning, Emerald Health Therapeutics Inc. announced that through Emerald Health Botanicals Inc., its wholly owned subsidiary and a Licensed Producer under the ACMPR, has submitted license applications to Health Canada for approval of two new cannabis cultivation sites. Emerald is preparing for the large-scale production of cannabis in anticipation of legalization of the adult-use cannabis market on July 1, 2018.
India Globalization Capital, Inc. (NYSE:IGC)
Today, India Globalization Capital, Inc. announced that the company has identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization of its “IGC-AD1” Alzheimer’s drug. The German market recently opened for imports of cannabis products that can be sold in licensed pharmacies, and the company’s initial research indicates that there are about 7.8 million patients with Alzheimer’s in these combined markets.
Tetra Bio-Pharma Inc. (TSXV:TBP) (OTC:TBPMF)
This morning, in conjunction with Aphria Inc., Tetra Bio-Pharma Inc. announced that it will start promoting a co-developed medical cannabis blend product under Health Canada’s Access to Cannabis for Medical Purposes Regulations, a.k.a. ACMPR. Tetra has signed a distribution agreement with Aphria to sell “Rx Princeps”, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.
This story originally appeared on The Daily Marijuana Observer: You can connect with them on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.
